

# EXHIBIT 29



**Heather L Mason**  
08/05/2003 08:08 PM

To: Jeffrey J Devlin/LAKE/PPD/ABBOTT@ABBOTT  
Subject: Re: Reyataz impact

FYI - Bill's response H

----- Forwarded by Heather L Mason/LAKE/PPD/ABBOTT on 08/05/2003 07:09 PM -----

**William G Dempsey**  
08/04/2003 07:26 PM

To: John B Thomas/LAKE/CORP/ABBOTT@ABBOTT  
cc: Heather L Mason/LAKE/PPD/ABBOTT@ABBOTT,  
jeff.leiden@abbott.com, William G  
Dempsey/LAKE/AI/ABBOTT@ABBOTT  
Subject: Re: Reyataz impact

John, this is still relevant but we must be credible and acknowledge that Atazanavir is having a good launch but that the product is best utilized ultimately on a niche basis for naive patients with uncontrolled lipids after the use of statins with Kaletra or possibly as adjunctive therapy with patients failing current treatment regimens. We need to acknowledge the market is looking for more convenient regimens as well and we are responding with reduced pill burden with our proprietary Meltrex technology and QD dosing with a registration study for Kaletra. We also need to point out the latest treatment guidelines which recommends Kaletras as the first PI to use. Heather and I will give this more thought as well. Bill D.  
John B Thomas

**John B Thomas**  
08/04/2003 10:43 AM

To: jeff.leiden@abbott.com@ABBOTT, William G  
Dempsey/LAKE/AI/ABBOTT@ABBOTT  
cc: Heather L Mason/LAKE/PPD/ABBOTT@ABBOTT  
Subject: Reyataz impact

Jeff and Bill -- Attached is the current IR Q&A response for questions concerning Reyataz's impact on Kaletra. We're getting some anxious investor calls about the data as analysts continue to see IMS reflecting a strong competitive start for Reyataz. The IR team has worked with PPD on the attached response, which we continue to use. I expect you'll also get questions on this at next Monday's investor visit. We're open to other positioning suggestions, if any. (A full briefing binder for the Monday meeting will be sent to you in the next few days.)



Reyataz response.doc

John B. Thomas  
Divisional Vice President  
Investor Relations  
john.b.thomas@abbott.com  
847.938.2655